BT3 Stock Overview
A clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Lineage Cell Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.00 |
52 Week High | US$1.28 |
52 Week Low | US$0.85 |
Beta | 1.31 |
11 Month Change | 0% |
3 Month Change | -7.41% |
1 Year Change | -18.70% |
33 Year Change | -58.33% |
5 Year Change | 8.51% |
Change since IPO | -42.86% |
Recent News & Updates
Recent updates
Shareholder Returns
BT3 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 5.1% | 0.4% |
1Y | -18.7% | -14.3% | 3.9% |
Return vs Industry: BT3 underperformed the German Biotechs industry which returned -14.3% over the past year.
Return vs Market: BT3 underperformed the German Market which returned 3.9% over the past year.
Price Volatility
BT3 volatility | |
---|---|
BT3 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BT3 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BT3's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 72 | Brian Culley | www.lineagecell.com |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
Lineage Cell Therapeutics, Inc. Fundamentals Summary
BT3 fundamental statistics | |
---|---|
Market cap | €161.52m |
Earnings (TTM) | -€22.14m |
Revenue (TTM) | €7.49m |
21.6x
P/S Ratio-7.3x
P/E RatioIs BT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BT3 income statement (TTM) | |
---|---|
Revenue | US$8.00m |
Cost of Revenue | -US$525.00k |
Gross Profit | US$8.53m |
Other Expenses | US$32.18m |
Earnings | -US$23.66m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 106.56% |
Net Profit Margin | -295.59% |
Debt/Equity Ratio | 0% |
How did BT3 perform over the long term?
See historical performance and comparison